Company news
Alzamend Neuro, Inc. news in 2024
Alzamend Neuro, Inc.'s news releases, calls and decks from 2024, newest first.
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
December 11, 2024
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
November 18, 2024
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
October 15, 2024
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
October 14, 2024
Alzamend Neuro Issues Letter to Stockholders
August 25, 2024
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
August 18, 2024
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
August 11, 2024
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease
August 5, 2024
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 5, 2024
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 4, 2024
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 30, 2024
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
May 21, 2024
Alzamend Neuro Announces Initial Closing of Private Placement
May 13, 2024
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
May 8, 2024
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
May 6, 2024
Decks in 2024
- Investor Presentation (May 2024)
Investor deck · 30 slides · May 15, 2024